Bellevue Life Sciences Acquisition Corp. Statistics
Share Statistics
Bellevue Life Sciences Acquisition Corp. has - shares outstanding. The number of shares has increased by -55.37% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -28.13% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.00M |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 735, so 0.02% of the outstanding shares have been sold short.
| Short Interest | 735 |
| Short % of Shares Out | 0.02% |
| Short % of Float | 0.04% |
| Short Ratio (days to cover) | 0.04 |
Valuation Ratios
The PE ratio is 146.22 and the forward PE ratio is null.
| PE Ratio | 146.22 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.82 |
| P/FCF Ratio | -72.11 |
| PEG Ratio | n/a |
Enterprise Valuation
Bellevue Life Sciences Acquisition Corp. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.01, with a Debt / Equity ratio of 0.
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.01% and return on capital (ROIC) is -2.41%.
| Return on Equity (ROE) | 0.01% |
| Return on Assets (ROA) | 0.01% |
| Return on Capital (ROIC) | -2.41% |
| Revenue Per Employee | - |
| Profits Per Employee | - |
| Employee Count | - |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 540.81K |
| Effective Tax Rate | 0.57 |
Stock Price Statistics
The stock price has increased by 8.12% in the last 52 weeks. The beta is -0.01, so Bellevue Life Sciences Acquisition Corp.'s price volatility has been lower than the market average.
| Beta | -0.01 |
| 52-Week Price Change | 8.12% |
| 50-Day Moving Average | 11.15 |
| 200-Day Moving Average | 10.84 |
| Relative Strength Index (RSI) | 51.46 |
| Average Volume (20 Days) | 11.04K |
Income Statement
In the last 12 months, Bellevue Life Sciences Acquisition Corp. had revenue of $0 and earned $403.78K in profits. Earnings per share was $0.07.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -1.83M |
| Net Income | 403.78K |
| EBITDA | 944.59K |
| EBIT | - |
| Earnings Per Share (EPS) | 0.07 |
Balance Sheet
The company has $15.42K in cash and $0 in debt, giving a net cash position of $15.42K.
| Cash & Cash Equivalents | 15.42K |
| Total Debt | 0 |
| Net Cash | 15.42K |
| Retained Earnings | -3.91M |
| Total Assets | 20.93M |
| Working Capital | -3.90M |
Cash Flow
In the last 12 months, operating cash flow was -$818.77K and capital expenditures -$4, giving a free cash flow of -$818.77K.
| Operating Cash Flow | -818.77K |
| Capital Expenditures | -4 |
| Free Cash Flow | -818.77K |
| FCF Per Share | -0.15 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
BLAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0.62% |
| FCF Yield | -1.79% |
Analyst Forecast
Currently there are no analyst rating for BLAC.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 3.59 |
| Piotroski F-Score | 1 |